XIAP and non-small cell lung carcinoma: An antisense oligonucleotide directed against XIAP (AEG35156) is in phase I/II clinical trials for patients with pancreatic, breast, non-small cell lung cancer, AML, lymphoma and solid tumours in which docetaxel is the drug of choice.